A CDC advisory committee again recommended against using AstraZeneca's FluMist for the upcoming flu season.
Weeks after announcing a €5.32 billion ($5.63 billion) buyout, German generics maker Stada said the deal failed to get shareholder approval.
Good news for Seattle Genetics and Takeda: Adcetris hit its goal in a Hodgkin lymphoma trial. Not so good? It didn't beat a standard regimen by much.
With a patent loss looming, Takeda filed a citizen petition pushing the FDA to knock back generic Velcade competition.
The FDA has approved Portola Pharmaceuticals’ factor Xa inhibitor Bevyxxa, but now the company is facing plenty of challenges as it gets the drug off the…
Can smartphones upend commerce in biopharma? AstraZeneca thinks they might. That's why it's in an AI pilot project that’s more healthcare than pharma.
Halfway into 2017, the FDA has beaten last year's drug-approvals tally with a crop featuring controversy, sales firepower and one very high price.
Pharma pulled in big Lions Health audiences with play-by-play case studies and frank talk. Dying commercial model? Creepy big data? Yes, and more.
Cannes means creativity in the advertising world, but pharma is still sitting on the sidelines.
The European Medicines Agency today recommended approval of Imraldi, a Humira biosimilar from Samsung and Biogen.